Literature DB >> 31372896

Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.

M C De Santis1, E La Rocca1,2, E Meneghini3, G Bregni4, G Di Lorenzo1,2, G Galli2,5, M Di Nicola5, S Folli6, M Gennaro6, G Pruneri2,7, B Paolini7, M G Daidone8, F De Braud2,9, G Apolone9, M Sant3, S Di Cosimo10.   

Abstract

BACKGROUND: Primary tumor characteristics, which are readily available to all clinicians, may aid in selecting the optimal adjuvant therapy for patients with breast cancer (BC). Herein, we investigated the relationship between tumor size, hormone receptor and HER2 status, Ki67 and age with axillary lymph node metastases (ALNM) in early-BC patients.
METHODS: We analyzed data on consecutive 2600 early-BC cases collected in the registry of Fondazione IRCC Istituto Nazionale dei Tumori, Milano, Italy. Correlation between Ki67 and primary tumor size (T-size) was calculated by Spearman's rank correlation coefficient. Association of ALNM with Ki67 and other tumor characteristics was investigated by logistic regression. Adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated in all cases, and separately analyzed according to age, T-size and BC subtype.
RESULTS: Large tumor size strongly associated to ALNM, with an adjusted odds ratio (OR) for each 5-mm increase of 1.32 (95% CI 1.24-1.41), except for triple-negative BC (TNBC) cases. In tumors =10 mm, without lymphovascular invasion, representing the strongest predictor of ALNM (OR 6.09, 95% CI 4.93-7.53), Ki67 resulted particularly informative, with a fourfold increased odds of ALNM for values > 30%.
CONCLUSIONS: These results raise the question whether axillary node status is redundant in cases with exceptionally good features, i.e., small tumors with low Ki67, or in those candidate to adjuvant systemic treatment/radiotherapy anyway including TNBC, and support the incorporation of primary BC tumor characteristics as stratification factors in ongoing trials aiming at de-escalating axillary surgical procedures.

Entities:  

Keywords:  Axillary node metastases; Breast cancer; Ki67; Primary tumor features

Mesh:

Substances:

Year:  2019        PMID: 31372896     DOI: 10.1007/s12094-019-02188-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  21 in total

1.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

Review 3.  HER2 as a prognostic and predictive marker for breast cancer.

Authors:  T Cooke; J Reeves; A Lanigan; P Stanton
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

Review 4.  Strategies for developing Ki67 as a useful biomarker in breast cancer.

Authors:  Carsten Denkert; Jan Budczies; Gunter von Minckwitz; Stephan Wienert; Sibylle Loibl; Frederick Klauschen
Journal:  Breast       Date:  2015-08-14       Impact factor: 4.380

5.  IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.

Authors:  Roopa Lakhanpal; Ivana Sestak; Bruce Shadbolt; Genevieve M Bennett; Michael Brown; Tessa Phillips; Yanping Zhang; Amanda Bullman; Angela Rezo
Journal:  Breast       Date:  2016-08-05       Impact factor: 4.380

6.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.

Authors:  Valerie-Jeanne Bardou; Grazia Arpino; Richard M Elledge; C Kent Osborne; Gary M Clark
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

Review 7.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

8.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.

Authors:  Patrick Maisonneuve; Davide Disalvatore; Nicole Rotmensz; Giuseppe Curigliano; Marco Colleoni; Silvia Dellapasqua; Giancarlo Pruneri; Mauro G Mastropasqua; Alberto Luini; Fabio Bassi; Gianmatteo Pagani; Giuseppe Viale; Aron Goldhirsch
Journal:  Breast Cancer Res       Date:  2014-06-20       Impact factor: 6.466

9.  Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer.

Authors:  Lin-Wei Guo; Lin-Miao Jiang; Yue Gong; Hong-Hua Zhang; Xiao-Guang Li; Min He; Wei-Li Sun; Hong Ling; Xin Hu
Journal:  Cancer Manag Res       Date:  2018-11-19       Impact factor: 3.989

10.  Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.

Authors:  C A Purdie; P Quinlan; L B Jordan; A Ashfield; S Ogston; J A Dewar; A M Thompson
Journal:  Br J Cancer       Date:  2013-12-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.